Interview with CELLPROTHERA, the regenerative medicine pioneer

02/04/2015 - 7 minutes

CellProthera is a medical biotech company founded in 2008 in Mulhouse, France. The young innovative company focuses on the use of blood peripheral stem cells. CellProthera is the origin of a revolutionary therapy allowing the regeneration of myocardial tissue following acute myocardial infarct (AMI) by injection of a cell graft containing autologous adult stem cells (ASC) previously selected and expanded – ProtheraCytes – in the myocardial muscle. Jean-Claude Jelsch, CEO at CellProthera since 2009, agreed to answer our questions.

What is your background?

I actually have an atypical background. I followed a course at the CNAM (Conservatoire national des arts et métiers) and at the same time I was working for the IT company Bull. Then, I followed a short course in a business school. After that, I worked for 32 years at Ecco (which then became Adecco). I had the opportunity to develop the French Great-East region and Germany, and contribute to diversity the activities of the group until 2000. Finally, I accepted to help the Hematology and Transplantation Research Institute (IRHT) created and managed by Prof.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member